Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 473 All time
- Disclosed funding
- $19.6B 400 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| OB Osanni BioCompany profile Platform that discovers and de-risks novel drug programs in ophthalmology and cardiology via affiliate company model Platform that discovers and de-risks novel drug programs in ophthalmology and cardiology via affiliate company model | $190M | Series B | Biotech | United States | Investors | |
| K KyrokCompany profile Builds an AI operating system for supply chain management in pharma and chemical SMEs across Europe Builds an AI operating system for supply chain management in pharma and chemical SMEs across Europe | €3.1M | Pre-SeedPre-seed | Biotech | Germany | Investors | |
| BP Bionyra PharmaCompany profile Bionyra Pharma develops biologic therapies for severe immunological and inflammatory diseases. Bionyra Pharma develops biologic therapies for severe immunological and inflammatory diseases. | $165M | Series A | Biotech | France | Investors | |
| D DropGenieCompany profile Miniaturizes gene editing workflows to enable direct edits on primary patient cells for cell therapy and drug discovery Miniaturizes gene editing workflows to enable direct edits on primary patient cells for cell therapy and drug discovery | Undisclosed | Seed+Seed | Biotech | Canada | Investors | |
| H HistoSonicsCompany profile Develops non-invasive histotripsy platform using focused ultrasound to mechanically destroy tumors without surgery Develops non-invasive histotripsy platform using focused ultrasound to mechanically destroy tumors without surgery | Undisclosed | StrategicUndisclosed | Biotech, Healthtech | United States | Investors | |
| LT Lys TherapeuticsCompany profile Develops monoclonal antibody LYS241 targeting neurovascular pathways for Parkinson's disease and stroke Develops monoclonal antibody LYS241 targeting neurovascular pathways for Parkinson's disease and stroke | >€25M | Seed | Biotech | France | Investors | |
| GT Graph TherapeuticsCompany profile Develops precision medicines for inflammatory and immune-mediated diseases using AI-powered patient cell analysis Develops precision medicines for inflammatory and immune-mediated diseases using AI-powered patient cell analysis | $5M | Series A | Biotech | Austria | Investors | |
| CB ChemT BiotechnologyCompany profile Develops AI virtual cell platform to optimize biomanufacturing processes for biopharma companies Develops AI virtual cell platform to optimize biomanufacturing processes for biopharma companies | $4M | Seed | Biotech | Singapore | Investors | |
| SB Syntax BioCompany profile Develops cell therapies using proprietary Cellgorithm platform for regenerative medicine Develops cell therapies using proprietary Cellgorithm platform for regenerative medicine | $14.4M | Series A+Series A | Biotech | United States | Investors | |
| PB Portal BiotechnologiesCompany profile Builds universal infrastructure for cell engineering across drug discovery and cell therapy Builds universal infrastructure for cell engineering across drug discovery and cell therapy | $9M | Undisclosed | Biotech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · All time
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
22rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.